$SCNI

Scinai Immunotherapeutics (SCNI) secured a $5.1M CDMO agreement with a US-listed biotech firm, boosting committed orders to $7.6M and extending revenue visibility to 2027. The deal covers oncology drug development and clinical manufacturing, with potential additional services valued at $5.85M. SCNI expects revenue recognition in 2026-2027, subject to performance obligations.

Scinai Immunotherapeutics (SCNI) regained compliance with Nasdaq's $1 minimum bid price requirement, as confirmed by Nasdaq. The company's ADSs closed at or above $1 for 19 consecutive days. CEO Amir Reichman stated the company will focus on commercial execution and NanoAb program advancement.

Scinai Immunotherapeutics (SCNI) ends its PC111 license agreement with PinCell, refocusing on its NanoAb platform and CDMO business. The company aims to allocate resources to its existing priorities, including a multi-program NanoAb platform and growing CDMO revenue. Scinai reported $3.1 million in committed CDMO orders and targets $5 million in 2026 revenue.

Scinai Immunotherapeutics Ltd. (SCNI) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, August 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai”

Scinai Immunotherapeutics (NASDAQ: SCNI) said its wholly owned CDMO unit, Scinai Biopharma Services, appointed Eran Kuratz as Head of Supply Chain and Business Process Administration. The role covers procurement, warehousing, logistics, budgeting, ERP/CRM/quality systems and cybersecurity. Scinai noted this supports integration and scale-up after its Q1 2026 Recipharm Israel acquisition.

Scinai Biopharma Services, a subsidiary of Scinai Immunotherapeutics (NASDAQ: SCNI), has appointed Eilon Elmalem as the Site Head of its Yavne CDMO facility, effective June 14, 2026. Elmalem brings over 20 years of biotechnology and pharmaceutical leadership experience from companies like Merck and Sigma-Aldrich Millipore. This appointment strengthens Scinai's focus on expanding its CDMO operations, following a transition overseen by the retiring site head, Dr. Sylvia Kachalsky.

Scinai Biopharma Services, a subsidiary of Scinai Immunotherapeutics Ltd., has appointed Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026. Elmalem brings over 20 years of experience in engineering and operations within the biotech and pharma industries, having previously consulted for Scinai on its CDMO activities. He will oversee site operations and engineering activities, supporting the growth of Scinai's CDMO platform, as Dr. Sylvia Kachalsky transitions towards retirement.

This page provides financial information for Scinai Immunotherapeutics Ltd. Sponsored ADR (FWB:2F5), specifically focusing on its tangible book value per share. The content is primarily a listing of financial data fields and links related to the company's stock performance and general TradingView platform features.

Scinai Immunotherapeutics Ltd. reported its full-year 2025 financial results, showing a doubling of CDMO revenues to $1.3 million and a strategic expansion of its CDMO platform through the acquisition of Recipharm Israel. The company also highlighted its focus on non-dilutive funding, including a resubmitted FENG grant application for its PC111 and IL-17 programs, and positioned PC111 as its flagship value driver. Despite a net loss for 2025 due to a non-recurring financial income in 2024, Scinai emphasized its operational growth and enhanced capabilities for diversified drug development and manufacturing services.

Grant funds two-thirds of a NIS 1.23 million ( $373K ) project to strengthen Scinai Bioservices' small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies in Israel and abroad